Evidence map›Paper›PMID 39337589›Full record

ArticleInternational journal of molecular sciences2024

Prevalence of Fabry Disease in Patients on Dialysis in France.

Florence Sens, Laure Guittard, Bertrand Knebelmann, Olivier Moranne, Gabriel Choukroun, Valérie de Précigout, Cécile Couchoud, Isabelle Deleruyelle, Léa Lancelot, Liên Tran Thi Phuong and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Florence SensService de Néphrologie et d'Explorations Fonctionnelles, Hôpital Edouard Herriot, Hospices Civils de Lyon, F-69003 Lyon, France.
Laure GuittardService Recherche et Epidémiologie Cliniques, Pôle Santé Publique, Hospices Civils de Lyon, F-69002 Lyon, France.
Bertrand KnebelmannService de Néphrologie, Hôpital Necker, Assistance Publique Hôpitaux de Paris, Université de Paris, F-75015 Paris, France.ORCID 0000-0002-8115-7303
Olivier MoranneService Néphrologie-Dialyse-Apherese, Hôpital Universitaire Caremeau, IDESP Université de Montpellier, F-30029 Nîmes, France.
Gabriel ChoukrounService de Néphrologie, Médecine Interne, Dialyse et Transplantation, CHU Amiens, F-80054 Amiens, France.
Valérie de PrécigoutService de Néphrologie, Hôpital Pellegrin, CHU Bordeaux, F-33076 Bordeaux, France.
Cécile CouchoudCoordination Nationale Réseau Epidémiologique et Information en Néphrologie, Agence de la Biomédecine, F-93212 Saint-Denis-La-Plaine, France.ORCID 0000-0002-9273-660X
Isabelle DeleruyelleService Recherche et Epidémiologie Cliniques, Pôle Santé Publique, Hospices Civils de Lyon, F-69002 Lyon, France.
Léa LancelotService Recherche et Epidémiologie Cliniques, Pôle Santé Publique, Hospices Civils de Lyon, F-69002 Lyon, France.
Liên Tran Thi Phuong"Geneo" Referral Center for Fabry Disease and Lysosomal Diseases, MetabERN European Reference Network, F-92380 Garches, France.
Thomas GhafariDivision of Medical Genetics, APHP-Paris Saclay University, F-92380 Garches, France.
Fabrydial Study Group
Laurent JuillardService de Néphrologie et d'Explorations Fonctionnelles, Hôpital Edouard Herriot, Hospices Civils de Lyon, F-69003 Lyon, France.
Dominique P Germain"Geneo" Referral Center for Fabry Disease and Lysosomal Diseases, MetabERN European Reference Network, F-92380 Garches, France.ORCID 0000-0002-8355-007X

Funding

Sanofi (France) Investigator Sponsored Study ISS
6 · The paper itself

Abstract

Numerous prevalence studies on Fabry disease (FD, OMIM #301500) have been conducted in dialysis populations across the world with variable and controversial results. The FABRYDIAL study aimed to estimate the prevalence of FD in patients aged 18 to 74 years on chronic dialysis in France. This cross-sectional study was conducted in patients undergoing dialysis. One hundred and twenty-four dialysis centers participated. Patients with proven causes of nephropathy unrelated to FD were excluded. Alpha-galactosidase A activity was assayed in men, and both α-galactosidase A and lyso-Gb

Indexed as

alpha-GalactosidaseFabry DiseaseRenal DialysisAdolescentAdultAgedCross-Sectional StudiesFemaleFranceGlycolipidsHumansMaleMiddle AgedPrevalenceSphingolipidsYoung Adultalpha-GalactosidaseGLA protein, humanglobotriaosyl lysosphingolipidGlycolipidsSphingolipidsdialysisFabry diseasegenetic variantsprevalencescreening

Identifiers

PMID39337589
PMCPMC11432483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.